JointHealth
français
 
JointHealth™ express   May 30, 2022

Let BC PharmaCare hear "Your Voice" on anifrolumab (Saphnelo™) for the treatment of systemic lupus erythematosus

Anifrolumab (Saphnelo™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about anifrolumab for the treatment of systemic lupus erythematosus.
You can give input if you are a B.C. resident and have systemic lupus erythematosus, a caregiver to someone with systemic lupus erythematosus, or if your group represents people who live with systemic lupus erythematosus.

If you would like our help in providing your input, you can email your comments to feedback@jointhealth.org or call us at 604-974-1366. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Friday, June 17 so that we may submit the questionnaire in time for the deadline.

The submission deadline is midnight on June 22, 2022. Patients and caregivers may give their input directly through the link below.

Please click on information sheet link below to learn more about anifrolumab and the questionnaire link below to let BC PharmaCare hear Your Voice:
  • To view the information sheet for anifrolumab for the treatment of systemic lupus erythematosus: click here
  • To complete the Questionnaire as a patient, caregiver, or patient group representative: click here